[en] We investigated whether secondary versus de novo acute myeloid leukaemia (AML) would be associated with poor outcomes in adult acute AML patients in first complete remission (CR1) receiving unrelated cord blood transplantation (CBT). This is a retrospective study from the acute leukaemia working party of the European Society for Blood and Marrow Transplantation. Inclusion criteria included adult at first allogeneic haematopoietic cell transplantation between 2000 and 2021, unrelated single or double unit CBT, AML in CR1, no ex vivo T-cell depletion and no post-transplant cyclophosphamide. The primary end-point of the study was leukaemia-free survival (LFS). A total of 879 patients with de novo (n = 696) or secondary (n = 183) AML met the inclusion criteria. In multivariable analyses, sAML patients had non-significantly different LFS (HR = 0.98, p = 0.86), overall survival (HR = 1.07, p = 0.58), relapse incidence (HR = 0.74, p = 0.09) and non-relapse mortality (HR = 1.26, p = 0.13) than those with de novo AML. Our results demonstrate non-significantly different LFS following CBT in adult patients with secondary versus de novo AML.
Disciplines :
Hematology
Author, co-author :
Baron, Frédéric ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'hématologie clinique
Nagler, Arnon ; Division of Hematology and Bone Marrow Transplantation, The Chaim Sheba Medical Center, Ramat-Gan, Israel
Galimard, Jacques-Emmanuel; EBMT Statistical Unit, Paris, France ; Department of Hematology, Saint Antoine Hospital, Paris, France ; INSERM UMR 938, Paris, France ; Sorbonne University, Paris, France
Sanz, Jaime; Hematology Department, University Hospital La Fe, Valencia, Spain
Versluis, Jurjen; Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands
Forcade, Edouard ; Service d'Hématologie Clinique et Thérapie Cellulaire, CHU Bordeaux, Bordeaux, France
Chevallier, Patrice ; Dept. D'Hematologie, CHU Nantes, Nantes, France
Sirvent, Anne; Département d'Hématologie Clinique, CHU Lapeyronie, Montpellier, France
Anthias, Chloe; Royal Marsden Hospital, Leukaemia Myeloma Units, London, UK
Kuball, Jürgen; Department of Haematology, University Medical Centre, Utrecht, The Netherlands
Furst, Sabine; Programme de Transplantation & Thérapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France
Rambaldi, Alessandro; Department of Oncology and Hematology, University of Milan and Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Milan, Italy
Sierra, Jorge; Hematology Department, Hospital Santa Creu i Sant Pau, Barcelona, Spain
von dem Borne, Peter A; Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands
Gallego Hernanz, Maria Pilar; Hematologic Oncology and Cellular Therapy Department, CHU Poitiers, Poitiers, France
Cluzeau, Thomas; CHU Nice-Hôpital de l'ARCHET I, Hematologie Clinique, Nice, France
Robinson, Stephen; Department of Paediatric Oncology/BMT, Bristol Royal Hospital for Children, Bristol, UK
Raiola, Anna Maria; Department of Haematology II, IRCCS Ospedale San Martino, Genova, Italy
Labussière-Wallet, Hélène; Hopital Lyon Sud, Hospices Civils de Lyon, Pierre Bénite, France
Byrne, Jenny L; Nottingham University, Nottingham, UK
Malfuson, Jean-Valère; Hôpital D'instruction des Armées (HIA) PERCY, Service d'Hématologie, Clamart, France
Ruggeri, Annalisa ; Ospedale San Raffaele s.r.l. Haematology and BMT, Milan, Italy
Mohty, Mohamad ; EBMT Statistical Unit, Paris, France ; Department of Hematology, Saint Antoine Hospital, Paris, France ; INSERM UMR 938, Paris, France ; Sorbonne University, Paris, France
Ciceri, Fabio ; Ospedale San Raffaele s.r.l. Haematology and BMT, Milan, Italy
Matthews A, Pratz KW. Optimizing outcomes in secondary AML. Hematology Am Soc Hematol Educ Program. 2022;2022:23–29.
Ramadan SM, Suciu S, Stevens-Kroef MJPL, Willemze R, Amadori S, de Witte T, et al. Survival improvement over time of 960 s-AML patients included in 13 EORTC-GIMEMA-HOVON trials. Cancer. 2020;12(11):3334.
Rampal R, Ahn J, Abdel-Wahab O, Nahas M, Wang K, Lipson D, et al. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proc Natl Acad Sci U S A. 2014;111:E5401–E5410.
Takahashi K, Wang F, Kantarjian H, Doss D, Khanna K, Thompson E, et al. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncol. 2017;18:100–111.
Schmaelter A-K, Labopin M, Socié G, Itälä-Remes M, Blaise D, Yakoub-Agha I, et al. Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia. Blood Cancer J. 2020;10:26.
Bleakley M, Riddell SR. Molecules and mechanisms of the graft-versus-leukaemia effect. Nat Rev Cancer. 2004;4:371–380.
Baron F, Labopin M, Savani BN, Beohou E, Niederwieser D, Eder M, et al. Graft-versus-host disease and graft-versus-leukaemia effects in secondary acute myeloid leukaemia: a retrospective, multicentre registry analysis from the Acute Leukaemia Working Party of the EBMT. Br J Haematol. 2020;188:428–437.
Milano F, Gooley T, Wood B, Woolfrey A, Flowers ME, Doney K, et al. Cord-blood transplantation in patients with minimal residual disease. N Engl J Med. 2016;375:944–953.
Baron F, Labopin M, Ruggeri A, Volt F, Mohty M, Blaise D, et al. Cord blood transplantation is associated with good outcomes in secondary Acute Myeloid Leukaemia in first remission. J Intern Med. 2019;285:446–454.
Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295–304.
Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission. Bone Marrow Transplant. 2016;51:610–611.
Canaani J, Labopin M, Itälä-Remes M, Blaise D, Socié G, Forcade E, et al. Prognostic significance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia. Leukemia. 2019;33:1944–1952.
Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–2919.
Hiwarkar P, Qasim W, Ricciardelli I, Gilmour K, Quezada S, Saudemont A, et al. Cord blood T cells mediate enhanced antitumor effects compared with adult peripheral blood T cells. Blood. 2015;126:2882–2891.
Baron F, Labopin M, Ruggeri A, Sierra J, Robinson S, Labussière-Wallet H, et al. Impact of detectable measurable residual disease on umbilical cord blood transplantation. Am J Hematol. 2020;95:1057–1065.
Ruggeri A, Labopin M, Savani B, Paviglianiti A, Blaise D, Volt F, et al. Hematopoietic stem cell transplantation with unrelated cord blood or haploidentical donor grafts in adult patients with secondary acute myeloid leukemia, a comparative study from Eurocord and the ALWP EBMT. Bone Marrow Transplant. 2019;54:1987–1994.
Nagler A, Labopin M, Blaise D, Raiola AM, Corral LL, Bramanti S, et al. Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT. J Hematol Oncol. 2023;16:58.
Pascal L, Mohty M, Ruggeri A, Tucunduva L, Milpied N, Chevallier P, et al. Impact of rabbit ATG-containing myeloablative conditioning regimens on the outcome of patients undergoing unrelated single-unit cord blood transplantation for hematological malignancies. Bone Marrow Transplant. 2015;50:45–50.
Baron F, Ruggeri A, Beohou E, Labopin M, Sanz G, Milpied N, et al. RIC versus MAC UCBT in adults with AML: a report from Eurocord, the ALWP and the CTIWP of the EBMT. Oncotarget. 2016;7:43027–43038.
Baron F, Ruggeri A, Beohou E, Labopin M, Mohty M, Blaise D, et al. Single- or double-unit UCBT following RIC in adults with AL: a report from Eurocord, the ALWP and the CTIWP of the EBMT. J Hematol Oncol. 2017;10:128.
Dholaria B, Labopin M, Sanz J, Ruggeri A, Cornelissen J, Labussière-Wallet H, et al. Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia. J Hematol Oncol. 2021;14:76.
Giannotti F, Labopin M, Shouval R, Sanz J, Arcese W, Angelucci E, et al. Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine. J Hematol Oncol. 2018;11:110.
Baron F, Labopin M, Ruggeri A, Cornelissen JJ, Meijer E, Sengeloev H, et al. Impact of donor type in patients with AML given allogeneic hematopoietic cell transplantation after low-dose TBI-based regimen. Clin Cancer Res. 2018;24:2794–2803.
Barker JN, Kurtzberg J, Ballen K, Boo M, Brunstein C, Cutler C, et al. Optimal practices in unrelated donor cord blood transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2017;23:882–896.
Eapen M, Wang T, Veys PA, Boelens JJ, St Martin A, Spellman S, et al. Allele-level HLA matching for umbilical cord blood transplantation for non-malignant diseases in children: a retrospective analysis. Lancet Haematol. 2017;4:e325–e333.
Petersdorf EW, Gooley T, Volt F, Kenzey C, Madrigal A, McKallor C, et al. Use of the HLA-B leader to optimize cord blood transplantation. Haematologica. 2021;106:3107–3114.
Ruggeri A, Galimard J-E, Labopin M, Rafii H, Blaise D, Ciceri F, et al. Comparison of outcomes after unrelated double-unit cord blood and haploidentical peripheral blood stem cell transplantation in adults with acute myelogenous leukemia: a study on behalf of Eurocord and the Acute Leukemia Working Party of the European Society for blood and marrow transplantation. Transplant Cell Ther. 2022;28:710.e1–710.e10.
Cohen S, Roy J, Lachance S, Delisle J-S, Marinier A, Busque L, et al. Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study. Lancet Haematol. 2020;7:e134–e145.
Horwitz ME, Stiff PJ, Cutler C, Brunstein C, Hanna R, Maziarz RT, et al. Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study. Blood. 2021;138:1429–1440.
Wagner JEJ, Brunstein CG, Boitano AE, DeFor TE, McKenna D, Sumstad D, et al. Phase I/II trial of StemRegenin-1 expanded umbilical cord blood hematopoietic stem cells supports testing as a stand-alone graft. Cell Stem Cell. 2016;18:144–155.
Cohen S, Bambace NM, Ahmad I, Burns LJ, Roy J, Lachance S, et al. Improved outcomes of UM171-expanded cord blood transplantation compared with other graft sources: real world evidence. Blood. 2022;140:1610–1612.
